Explore the research.
Find a compound, understand the evidence, and read the original studies.
Compound profiles
Mechanisms, evidence limits, and original references.
- Single compound
5-Amino-1MQ
Small-molecule NNMT inhibitor
5-amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase investigated in biochemical assays, adipocyte cultures and mouse models of diet-induced obesity.
Evidence contextRead research profileBiochemical, cell and animal evidence
- Single compound
AOD-9604
Growth-hormone-derived peptide fragment
AOD-9604 is a modified growth-hormone fragment studied primarily in experimental lipid-metabolism models and analytical investigations of peptide breakdown.
Evidence contextRead research profileAnimal and analytical evidence in the cited studies
- Single compound
ARA-290
Erythropoietin-derived signaling peptide
ARA-290, also known as cibinetide, is an erythropoietin-derived peptide studied in tissue-protection models and small human trials of sarcoidosis-associated neuropathy.
Evidence contextRead research profilePreclinical rationale and small human trials
- Single compound
BPC-157
Experimental pentadecapeptide
BPC-157 is a synthetic 15-residue peptide studied mainly in laboratory models of tissue injury, with clinical efficacy remaining unestablished.
Evidence contextRead research profilePreclinical evidence; human benefit unestablished
- Single compound
Cagrilintide
Amylin and calcitonin receptor agonist
Cagrilintide is a long-acting amylin analogue studied in receptor pharmacology and human weight-management trials, both alone and alongside semaglutide.
Evidence contextRead research profileHuman trials with mechanistic receptor studies
- Single compound
CJC-1295 no DAC
GHRH analogue; identity qualification required
CJC-1295 no DAC is a catalog designation for a GHRH-related peptide that must be distinguished from the albumin-binding, long-acting CJC-1295 used in published human trials.
Evidence contextRead research profileRelated-compound evidence; no-DAC identity unconfirmed
- Research blend
CJC-1295 no DAC + Ipamorelin
GHRH-family and ghrelin-receptor research blend
This blend lists CJC-1295 without DAC and ipamorelin, linking two receptor pathways studied in pituitary growth-hormone secretion and short-term endocrine responses.
Evidence contextRead research profileComponent evidence · finished blend untested in cited studies
- Single compound
Dihexa
Experimental angiotensin IV-related peptidomimetic
Dihexa is an experimental peptidomimetic with preclinical neural findings, but retraction of a central mechanism paper substantially complicates interpretation.
Evidence contextRead research profilePreclinical findings; central mechanism paper retracted
- Single compound
DSIP
Experimental sleep-related nonapeptide
DSIP is a nine-residue peptide investigated through animal sleep physiology and small human experiments, with inconsistent evidence for meaningful sleep benefit.
Evidence contextRead research profileSmall historical human studies; uncertain benefit
- Single compound
GHK-Cu
Copper-binding tripeptide complex
GHK-Cu is a copper complex of glycyl-histidyl-lysine studied for its effects on extracellular-matrix production and remodeling in experimental tissue-repair systems.
Evidence contextRead research profileFoundational cell and animal evidence
- Single compound
GHRP-2
Ghrelin-receptor agonist
GHRP-2 is a synthetic growth hormone secretagogue investigated as a probe of GH release, appetite, and the interaction between ghrelin and GHRH signaling.
Evidence contextRead research profileSmall human physiology studies
- Single compound
GHRP-6
Growth hormone secretagogue peptide
GHRP-6 is a synthetic hexapeptide used to study growth hormone release, its interaction with endogenous GHRH, and broader neuroendocrine responses.
Evidence contextRead research profileHuman endocrine and sleep physiology studies
- Research blend
GLOW
Copper-peptide and tissue-signaling research blend
GLOW groups GHK-Cu, BPC-157 and a TB-500-listed component, bringing together separate lines of matrix-remodeling and tissue-signaling research.
Evidence contextRead research profileComponent evidence · finished blend untested in cited studies
- Single compound
Glutathione
Endogenous thiol tripeptide
Glutathione is an endogenous tripeptide involved in redox balance, with human supplementation studies reporting variable changes in glutathione pools and metabolic biomarkers.
Evidence contextRead research profileHuman biomarker trials with mixed results
- Single compound
IGF-1 LR3
Modified IGF-1 analogue
IGF-1 LR3 is an engineered IGF-1 analogue used mainly in laboratory studies of growth-factor signaling, binding proteins, and tissue proliferation.
Evidence contextRead research profileCell and animal evidence
- Single compound
Ipamorelin
Ghrelin-receptor agonist
Ipamorelin is a synthetic pentapeptide studied for growth hormone secretion and gastrointestinal motility, with early human physiology work and a postoperative-ileus trial.
Evidence contextRead research profilePreclinical pharmacology and limited human trials
- Single compound
Kisspeptin
KISS1-derived peptide family; sequence pending
Kisspeptin denotes a peptide family involved in reproductive signaling; the catalog's unspecified sequence cannot yet be matched to trials of kisspeptin-10 or kisspeptin-54.
Evidence contextRead research profileHuman evidence for defined forms; catalog identity unresolved
- Research blend
KLOW
Four-component matrix and inflammatory-signaling research blend
KLOW lists GHK-Cu, BPC-157, TB-500 and KPV, connecting component studies of skin-matrix remodeling, cell migration and intestinal inflammatory signaling.
Evidence contextRead research profileComponent evidence · finished blend untested in cited studies
- Single compound
KPV
Alpha-MSH-derived tripeptide
KPV is a three-residue fragment of alpha-MSH studied for cellular inflammatory signaling and intestinal inflammation in preclinical models.
Evidence contextRead research profileCell and animal evidence; clinical efficacy unestablished
- Single compound
LL-37
Human cathelicidin host-defense peptide
LL-37 is a human host-defense peptide with immune-signaling research and a venous-ulcer trial that found no significant benefit across its full study population.
Evidence contextRead research profileCell evidence and a human trial with a negative overall result
- Single compound
Melanotan I
Alpha-MSH analogue
Melanotan I is an alpha-MSH analogue studied in pigmentation biology; clinical afamelanotide implant research must be distinguished from a catalog research material.
Evidence contextRead research profileHuman studies; formulation-specific clinical evidence
- Single compound
Melanotan II
Cyclic melanocortin analogue
Melanotan II is a cyclic alpha-MSH analogue investigated in early human studies of pigmentation and sexual physiology, with effects extending beyond pigment production.
Evidence contextRead research profileSmall early human trials
- Research blend
Metabolic blend
Coenzyme, mitochondrial peptide and NNMT-inhibitor research blend
The Metabolic Blend lists NAD+, MOTS-c and 5-amino-1MQ, connecting three distinct research topics in cellular energetics and nicotinamide metabolism.
Evidence contextRead research profileComponent evidence · finished blend untested in cited studies
- Single compound
MGF
Experimental IGF-1 E-domain peptide
MGF refers to an IGF-1-related research concept and synthetic E-domain peptides whose proposed independent muscle effects have conflicting experimental support.
Evidence contextRead research profileConflicting cell evidence; human data concern endogenous expression
- Single compound
MOTS-C
Mitochondrial-derived signaling peptide
MOTS-c is a mitochondrial-derived peptide studied in metabolic signaling and skeletal-muscle adaptation, with experimental interventions supported mainly by cell and animal evidence.
Evidence contextRead research profilePreclinical interventions; human physiological observations
- Single compound
NAD+
Redox coenzyme
NAD+ is an endogenous coenzyme central to cellular energy and signaling, with research spanning mitochondrial transport, aging biology and the metabolism of administered NAD+.
Evidence contextRead research profileHuman metabolism and tissue studies with cell evidence
- Single compound
Oxytocin
Endogenous neuropeptide hormone
Oxytocin is a nine-residue hormone studied in peripheral reproductive physiology and context-dependent social signaling; behavioral findings do not imply a universal trust or bonding effect.
Evidence contextRead research profileMechanistic studies and mixed human trial results
- Single compound
PEG-MGF
Modified IGF-I E-peptide research
PEG-MGF refers to a modified mechano-growth-factor peptide, but related E-peptide studies show conflicting cell results and do not establish the behavior of an unspecified PEG conjugate.
Evidence contextRead research profileConflicting parent-peptide evidence; PEG construct unresolved
- Single compound
PT-141
Melanocortin-receptor agonist
PT-141, also called bremelanotide, is a melanocortin agonist studied in sexual-function research, including controlled trials in a narrowly defined clinical population.
Evidence contextRead research profileHuman randomized trials for a specified clinical formulation
- Single compound
Retatrutide
GLP-1, GIP and glucagon receptor agonist
Retatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
Evidence contextRead research profileHuman trials with supporting preclinical pharmacology
- Single compound
Selank
Tuftsin-derived regulatory peptide
Selank is a synthetic tuftsin-derived heptapeptide studied in neurotransmission models and a small anxiety trial, with its direct molecular targets and wider clinical effects still uncertain.
Evidence contextRead research profilePreclinical mechanisms with limited human trial evidence
- Research blend
Selank + Semax
Tuftsin-derived and ACTH-fragment-derived peptide research blend
Selank + Semax pairs two distinct synthetic peptides studied in neural signaling, with component-level findings that do not establish effects of the finished combination.
Evidence contextRead research profileComponent evidence · finished blend untested in cited studies
- Single compound
Semaglutide
GLP-1 receptor agonist
Semaglutide is a modified GLP-1 analogue with receptor-level research and substantial human trial evidence for specific weight-related and cardiovascular outcomes.
Evidence contextRead research profileLarge human trials and molecular pharmacology
- Single compound
Semax
ACTH-fragment-derived heptapeptide
Semax is a synthetic ACTH-fragment-derived peptide investigated for neurotrophin signaling and responses to experimental brain injury, with strongly time- and tissue-dependent findings in rodent studies.
Evidence contextRead research profilePredominantly preclinical neurotrophin evidence
- Single compound
Sermorelin
GHRH(1–29) peptide
Sermorelin is the amidated GHRH(1–29) fragment, investigated as a probe of pituitary responsiveness and in historical pediatric growth studies.
Evidence contextRead research profileHistorical human endocrine and pediatric studies
- Single compound
SLU-PP-332
Small-molecule estrogen-related receptor agonist
SLU-PP-332 is a synthetic small molecule studied as an estrogen-related receptor agonist in cellular energy metabolism and mouse exercise and obesity models.
Evidence contextRead research profileCell and mouse evidence
- Single compound
SNAP-8
Synthetic acetylated cosmetic octapeptide
SNAP-8 denotes acetyl octapeptide-3, studied within multicomponent cosmetic formulations; those studies cannot isolate its effects or establish the mechanism proposed from related hexapeptide research.
Evidence contextRead research profileHuman formulation studies; isolated effect unresolved
- Single compound
SS-31
Mitochondria-targeting tetrapeptide
SS-31, known clinically as elamipretide, is a tetrapeptide studied for interactions with mitochondrial cardiolipin and for disease-specific functional outcomes.
Evidence contextRead research profileMechanistic evidence and disease-specific human trials
- Single compound
TB-500 (Short Chain)
Thymosin beta-4-derived heptapeptide
Short-chain TB-500 is associated with an acetylated seven-residue thymosin beta-4 fragment; analytical identification does not establish the therapeutic effects often inferred from the full-length parent peptide.
Evidence contextRead research profileAnalytical fragment evidence; parent biology is indirect
- Single compound
Tesamorelin
GHRH analogue
Tesamorelin is a stabilized GHRH analogue studied for changes in visceral and liver fat, principally in people with HIV-associated abdominal adiposity.
Evidence contextRead research profileHuman randomized trials in defined populations
- Research blend
Tesamorelin + Ipamorelin
GHRH analogue and growth-hormone secretagogue research blend
Tesamorelin + Ipamorelin combines two distinct endocrine research materials, with clinical evidence for individual compounds that does not validate the combined formulation.
Evidence contextRead research profileComponent evidence · finished blend untested in cited studies
- Single compound
Thymosin alpha-1
Immunomodulatory peptide
Thymosin alpha-1 is a 28-residue peptide investigated in immune-cell signaling and clinical immunomodulation, with promising experimental findings but a negative large sepsis trial.
Evidence contextRead research profilePreclinical mechanisms; mixed clinical translation
- Single compound
Thymosin Beta-4 (Long Chain)
Actin-binding thymosin peptide
Thymosin beta-4 is a 43-residue actin-binding peptide studied in cell migration, experimental tissue injury, and ophthalmic formulations, with clinical conclusions constrained by trial-specific endpoints.
Evidence contextRead research profileEstablished actin biology; indication-specific clinical uncertainty
- Single compound
Tirzepatide
GIP and GLP-1 receptor agonist
Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in molecular pharmacology and large human trials of glycemic control and body weight.
Evidence contextRead research profileLarge human trials with translational pharmacology
- Research blend
Wolverine
BPC-157 and thymosin-related research blend
Wolverine pairs BPC-157 with a TB-500-listed component, connecting preclinical tendon and gastrointestinal research with thymosin-related identity questions. The exact TB-500 sequence still requires confirmation.
Evidence contextRead research profileComponent evidence · finished blend untested in cited studies
- Research blend
Wolverine+
BPC-157, thymosin-related and IGF-1 E-peptide research blend
Wolverine Plus adds an MGF-listed component to BPC-157 and TB-500, bringing together distinct research lines with important sequence and replication uncertainties.
Evidence contextRead research profileComponent evidence · finished blend untested in cited studies
- Research blend
Wolverine+ with KPV
Four-component repair and inflammatory-signaling research blend
This formulation lists BPC-157, TB-500, MGF and KPV, with evidence limited to separate component studies and unresolved quantity and molecular-identity details.
Evidence contextRead research profileComponent evidence · finished blend untested in cited studies
These profiles describe the published literature. They do not establish the identity, test results or suitability of any WYZ lot. Review batch documentation.
From the notebook
Practical notes on documentation and laboratory research materials.
Documentation · 3 min read
A closer look at a Certificate of Analysis.
The details to look for, from product identity to the lot on your label.
Read the noteResearch essentials · 2 min read
Small number. Important connection.
Why a lot number belongs alongside every material record.
Read the noteThe fundamentals · 2 min read
Research use, clearly defined.
A shared understanding of the purpose and scope of this collection.
Read the note